1Y Close · As of Aug 26, 2026
Neopharm operates in the Chemicals sector.
Legal name: NeopharmCO.,LTD.
In fiscal year 2025, Neopharm (092730) reported revenue of 132.2 billion KRW, up 11.1% from 119.0 billion KRW a year earlier.
Operating profit was 28.8 billion KRW and net income was 27.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 375.1 billion KRW, with a P/B of 1.92.
These figures can be verified in the DART filing (receipt no. 20260316001522).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 132.2B | 28.8B | 27.8B |
| 2024 | 119.0B | 24.7B | 23.1B |
| 2023 | 97.1B | 25.3B | 23.2B |
| 2022 | 85.0B | 21.4B | 17.0B |
| 2021 | 87.9B | 22.4B | 17.7B |
Recent Filings
Corporate Briefing (IR)
Semi-Annual Report (2026.06)
Operating (Preliminary) Earnings (Fair Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Corporate Briefing (IR) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Operating (Preliminary) Earnings (Fair Disclosure) |